Locus Biosciences Revenue and Competitors

Location

$93.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Locus Biosciences's estimated annual revenue is currently $5.4M per year.(i)
  • Locus Biosciences's estimated revenue per employee is $86,111
  • Locus Biosciences's total funding is $93.7M.

Employee Data

  • Locus Biosciences has 63 Employees.(i)
  • Locus Biosciences grew their employee count by 13% last year.

Locus Biosciences's People

NameTitleEmail/Phone
1
Co-founder and CEOReveal Email/Phone
2
Chief Technology OfficerReveal Email/Phone
3
Chief Financial OfficerReveal Email/Phone
4
Associate VP, Research and Development Program ManagmentReveal Email/Phone
5
VP TechnologyReveal Email/Phone
6
VP, R&D Program ManagementReveal Email/Phone
7
VP Pharmaceutical Operations and TechnologyReveal Email/Phone
8
VP, Research and DevelopmentReveal Email/Phone
9
VP Clinical Operations and CMC OperationsReveal Email/Phone
10
Director Automation and InformaticsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.2M637%N/AN/A
#2
$5099.8M32902-4%N/AN/A
#3
$1.7M110%N/AN/A
#4
$0.6M4-56%N/AN/A
#5
N/A157%N/AN/A
#6
$0.9M11-39%N/AN/A
#7
$1.7M90%N/AN/A
#8
$0.6M30%N/AN/A
#9
$4.8M31-6%N/AN/A
#10
$6.4M366%N/AN/A
Add Company

What Is Locus Biosciences?

Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating a small strand of RNA called a CRISPR RNA, which matches a DNA sequence specific to a given invader. If the CRISPR RNA is matched to a complementary DNA sequence, the Cas proteins will cleave the invading DNA.

keywords:N/A

$93.7M

Total Funding

63

Number of Employees

$5.4M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Locus Biosciences News

2022-04-13 - Phage Therapy Market Size [2022-2028] | is Projected to Reach USD 100.8 Million, with 17.6% CAGR | Growth Rate, Share, New Developments, Market Dynamics, Key Players, Revenue, and Expansion Plans, Research | Market Reports World

... Proteon Pharmaceuticals, Phagelux, Intralytix, Micreos, Eliava BioPreparations, Locus Biosciences,Inc, Pharmex Group,LLC and many more.

2016-02-04 - EpiBiome Completes $6M Series A Financing

EpiBiome, a South San Francisco, CA-based precision microbiome engineering company, completed a $6m Series A financing. Backers included Viking Global Investors via the Illumina Accelerator Boost Capital, Matrix Capital Management, Alexandria Venture Investments, SV Tech Ventures and China Rock ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$21.6M635%N/A
#2
$5.7M6337%N/A
#3
$8.6M6324%N/A
#4
$9.3M63-7%N/A
#5
$11.8M647%N/A